ChinaBio® Report: 2020 China Life Science Investment Hits New Records

In 2020, investment in China life science showed stellar growth. ChinaBio®'s survey  shows four of the five investment categories set new records, often doubling the year-earlier comparison, while the fifth, Mergers & Acquisitions, fell for the second year in a row:  VC/PE Fundraising: $56.1 billion; 2.3 times 2019; VC/PE Investments: $28.5 billion; 2.0 times 2019; IPOs: $23.3 billion; 2.9 times 2019; Partnering: $30.5 billion; 1.7 times 2019; Mergers and Acquisitions: $9.7 billion; a 60% drop from 2019. Between VC/PE investors and IPOs, there is a lot of capital available to young life science companies, which may explain why M&A underperformed so dramatically. With so much capital support readily available, owners of young life science companies have little reason to merge or sell their companies to competitors. More details....